BeyondSpring Inc

-0.61 (-3.88%)
Earnings Announcements

BeyondSpring Reports Exclusive Agreement with Jiangsu Hengrui Pharma for Plinabulin in Greater China

Published: 08/26/2021 11:18 GMT
BeyondSpring Inc (BYSI) - Beyondspring Announces Exclusive Commercialization and Co-development Agreement With Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China.
Beyondspring Inc - Wanchunbulin to Receive Up to 1.3b Rmb (est.
$200m Usd) in Milestone Payments.
Beyondspring Inc - Hengrui to Pay for 100% of Commercialization Costs for Plinabulin in Territory and Receive a Pre-determined Percentage of Net Sales.
Beyondspring Inc - Hengrui to Make 100m Rmb Equity Investment in Wanchunbulin at a Pre-money Valuation of 3.6b Rmb.
Beyondspring Inc - Wanchunbulin to Book Revenue and to Pay for 100% Cost of Goods Sold.
Revenue is expected to be $3.83 Million
Adjusted EPS is expected to be -$0.55

Next Quarter Revenue Guidance is expected to be $2.86 Million
Next Quarter EPS Guidance is expected to be -$0.65

More details on our Analysts Page.